Pre-made Rovelizumab benchmark antibody (Bispecific, anti-ITGAL;ITGB2 therapeutic antibody, Anti-CD11A/LFA-1/LFA1A;CD18/LAD/LCAMB/LFA-1/MAC-1/MF17/MFI7 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Rovelizumab benchmark antibody (Bispecific, anti-ITGAL;ITGB2 therapeutic antibody, Anti-CD11A/LFA-1/LFA1A;CD18/LAD/LCAMB/LFA-1/MAC-1/MF17/MFI7 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Rovelizumab, also known as LeukArrest and Hu23F2G, is a humanized monoclonal antibody which was an experimental immunosuppressive drug. Rovelizumab was developed by Icos to treat patients suffering from haemorrhagic shock.[2] The drug is a monoclonal antibody that suppresses white blood cells which become overly active during shock.[3][4] During testing the number of patients given the drug was low because rovelizumab had to be delivered within four hours of the injury and consent was required.[4] Often the patient was unconscious and relatives had to be reached to give consent.[4] In June 1998, Icos and many medical centers asked the United States Food and Drug Administration (FDA) to waive consent requirements in situations where the patient was at high risk of dying and relatives could not be reached.[4] While some medical ethicists opposed waiving consent, the FDA approved the proposal in August 1998 for five medical centers.[5][6] Development of rovelizumab was halted in April 2 when interim data from phase III clinical trials did not meet Icos's goals.[7] The company's goals for rovelizumab included reducing the chance of multiple organ failure and reducing the death-rate from shock at 28 days.[2] Rovelizumab was also being tested for treating heart attack, multiple sclerosis, and stroke, and was being explored as a treatment for cerebral vasospasm, head trauma, kidney transplantation, and restenosis.[1]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-981-1mg	1mg	Inquiry
GMP-Bios-INN-981-10mg	10mg	Inquiry
GMP-Bios-INN-981-100mg	100mg	Inquiry
GMP-Bios-INN-981-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Rovelizumab Biosimilar, Bispecific, Anti-Itgal;Itgb2 Antibody: Anti-CD11A/LFA-1/LFA1A;CD18/LAD/LCAMB/LFA-1/MAC-1/MF17/MFI7 therapeutic antibody
INN Name	Rovelizumab
Target	ITGAL;ITGB2
Format	Bispecific
Derivation
Species Reactivity
CH1 Isotype
VD LC
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech